LEOBENDORF, Austria, January 27, 2022--(BUSINESS WIRE)--Croma-Pharma (Croma), today announced that the decentralized procedure for its botulinum toxin to gain market authorization in Europe has been accomplished. This important step is the basis to complete Croma’s already comprehensive portfolio.

Croma’s botulinum toxin submission in Europe is based on the data of 3 completed randomized, placebo-controlled phase III trials that enrolled a total of >1000 subjects in Europe and the US. National phases to grant the market authorization across Europe are following now.

A game changer for Croma-Pharma and the aesthetic industry

By adding its own botulinum toxin to the already broad portfolio Croma catapults itself to a new level within the aesthetic industry.

Offering already a wide selection of HA fillers, PDO threads, PRP and scientific skincare products, the botulinum toxin was the missing piece to compete with world leaders in this sector.

"We are pleased to announce that our toxin has now accomplished the decentralized procedure in Europe and will continue with the market authorization in major European countries in the next months. With this, we will now be able to complete our portfolio to meet all the needs of our customers", Managing Director Andreas Prinz points out.

Partnership with Hugel Croma has licensed the product from the Korean toxin producer Hugel Inc. for Europe and established a joint venture company in 2018 with Hugel, Inc., in order to develop and commercialize Croma’s HA filler products together with Hugel’s botulinum toxin product in the US, Canada, Australia and New Zealand.

About Croma Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.

About Hugel, Inc. Established in Korea in 2001, Hugel is a global leader in medical aesthetics providing botulinum toxin formulation under different brand names such as BOTULAX and LETYBO in numerous countries across the world. Dedicated to provide proven, high quality medical aesthetic solutions that satisfy both consumers’ and practitioners’ needs, Hugel is leading the Korean market with its botulinum toxin.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005535/en/

CROMA-PHARMA GmbH Michael Donhofer Director Global Marketing & Public Relation Phone: +43 676 84 68 68 823 Mail: michael.donhofer@croma.at Web: www.croma.at

As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current

Nuclear submarine supplier to be sold to US buyer after diplomatic row Russian default expected within days Retail sales volumes down 0.5pc in May FTSE 100 rises strongly Ambrose Evans-Pritchard: The pro-Brussels establishment is painting Brexit as an economic disaster to reverse it Sign up here for our daily business briefing newsletter

When you need another stream of income for retirement, you might consider an annuity. You purchase the annuity from an insurance company and receive payments back at a later date. Before buying an annuity, it's important to consider how much … Continue reading → The post How Much Does a $300,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.

Shares of the specialty pharmaceutical company Bausch Health Companies (NYSE: BHC) are surging today in response to the news that Joseph Papa has resigned from the board of directors effective immediately. Over the past six years, Papa has been instrumental in lowering the company's sky-high debt and keeping it out of bankruptcy court. Bausch said in a statement Thursday evening that billionaire hedge fund manager John Paulson will fill the vacant board position.

In this article, we will take a look at 10 value stocks to buy according to billionaire David Tepper. If you want to skip our discussion on Tepper’s history and his hedge fund’s performance, go directly to 5 Value Stocks to Buy According to Billionaire David Tepper. With a net worth of $16.7 billion, David […]

“Time is running out for cash-burning companies kept afloat with easy access to capital,” New Constructs CEO David Trainer said in a Thursday research note.

High-yield dividend stocks are a major component of my stock portfolio. Here are three income stocks that have room for solid gains in the next year and even better gains over the long run. The blue-chip business development company (BDC) Main Street Capital (NYSE: MAIN) has held up better than the S&P 500 index, which is down 21% so far this year.

Mr Musk now has access to real-time data that could be the last hurdle ahead of his buyout

The days of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) stock trading above $2,000 are numbered. Investors often eagerly anticipate stock splits because they think shares could take off after the split. Let's first address the significance (or lack thereof) of stock splits.

Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.

In this article, we will look at 10 stocks to profit from inflation. If you want to explore similar stocks, you can also read 5 Stocks to Profit from Inflation. Billionaire investor and hedge fund manager of the world’s largest hedge fund, Bridgewater Associates, Ray Dalio shared his views on the current economic situation that […]

Energy prices are high. But bargain-hunter Buffett continues to bet on big oil.

The merger between the special-purpose acquisition company Gores Guggenheim and the electric-vehicle company coming from Volvo is done.

At current levels, investors need a 7% to 8% return just to preserve their wealth.

Shares of CalAmp (NASDAQ: CAMP) were tumbling today after the company reported first-quarter results that missed Wall Street's top- and bottom-line expectations. CalAmp reported a non-GAAP (adjusted) loss per share of $0.10 in the quarter, which was much worse than analysts' consensus estimate of a loss of $0.03. The company's revenue of $64.7 million -- a decrease of nearly 19% from the year-ago quarter -- was also below Wall Street's average estimate of $69.4 million.

As Netflix cuts costs to ease subscriber-loss pains, more jobs have been scrapped.

Russia’s fiddling with gas flows to Europe could create an economic spillover effect, warns Germany’s top economy minister.

Downturns can bring a lot of pain, but they can also bring on plenty of opportunities, as lower stock prices start making costs of entry more attractive. Before taking advantage of these opportunities, however, investors need to find a recognizable signal that will set them apart. One popular signal to follow is the insider buying, the trades made by high-ranking company officers whose positions give them the ‘inside’ track on their company’s likely prospects – and therefore, of the stock’s pros

Weitz Investment Management, an investment management firm, published its “Partners III Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. The Partners III Opportunity Fund’s Institutional Class returned -5.09% in the first quarter of 2022 compared with -4.60% for the S&P 500 and -5.28% for the Russell 3000. […]

Yahoo Finance Live's Dave Briggs looks at the potential delays Intel's Ohio factory may face due to the CHIPS Act passed by Congress.